

VANGUARD RESEARCH GROUP NEWSLETTER

August 2023

VRG IS RUNNING A SURVEY TO GIVE YOU DATA ON YOUR OWN PATIENT POPULATION!

Through August and September, we are offering our partner agencies the opportunity to let their patients complete a brief 3-minute survey, rating their difficulty in completing 11 basic healthcare related tasks. Participant data is anonymized and shared with your site for your own patient population along with cumulative data for all patients and sites.

We hope to help you gain more insight into the tasks your patients might need extra support with!

Participation is free and easy – just let us know you are interested, and we will send you a flyer with a link/QR code that you can distribute at your agency for patients to complete at their convenience.



NEW LAI RECEIVED FDA APPROVAL FOR THE TREATMENT OF SCHIZOPHRENIA

The new long-acting injectable medication, UZEDY, uses an innovative slow-release mechanism and is administered in pre-filled syringes. Studies show it could reduce relapse by up to 80%. Read more about it here:

https://www.psychiatrist.com/news/slow-release-uzedy-gains-fda-approval-reduces-schizophrenia-relapse-by-80/?dm_i=6T7Q,SJKT,4ZNO6R,3JMB1,1

WE HAVE CURRENT PROJECTS SEEKING ADDITIONAL SITES!

- A novel pharmacological treatment for cognitive impairment for schizophrenia patients
- An observational study to evaluate the clinical course and treatment of tardive dyskinesia (TD).
 - Questionnaires to assess the impact of TD on quality of life, sites and clients are reimbursed to participate
- A novel pharmacological treatment for schizophrenia
- New psychosocial technology treatments for negative symptoms

If you are interested in learning more or participating, please email Ben George at bgeorge7@northwell.edu.

CHECK OUT OUR NEW WEBSITE www.vanguardresearchgroup.com AND FOLLOW US ON SOCIAL MEDIA



<https://www.linkedin.com/company/vanguardresearchgroup>



<https://twitter.com/VRGResearch>



<https://www.facebook.com/VRGResearch/>